tetano
Editor, Senior Moderator
Virology. 2016 Aug 17;498:36-43. doi: 10.1016/j.virol.2016.08.010. [Epub ahead of print]
[h=1]Cross-protective efficacies of highly-pathogenic avian influenza H5N1 vaccines against a recent H5N8 virus.[/h] Park SJ[SUP]1[/SUP], Si YJ[SUP]1[/SUP], Kim J[SUP]2[/SUP], Song MS[SUP]1[/SUP], Kim SM[SUP]1[/SUP], Kim EH[SUP]1[/SUP], Kwon HI[SUP]1[/SUP], Kim YI[SUP]1[/SUP], Lee OJ[SUP]1[/SUP], Shin OS[SUP]3[/SUP], Kim CJ[SUP]4[/SUP], Shin EC[SUP]2[/SUP], Choi YK[SUP]5[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] To investigate cross-protective vaccine efficacy of highly-pathogenic avian influenza H5N1 viruses against a recent HPAI H5N8 virus, we immunized C57BL/6 mice and ferrets with three alum-adjuvanted inactivated whole H5N1 vaccines developed through reverse-genetics (Rg): [Vietnam/1194/04xPR8 (clade 1), Korea/W149/06xPR8 (clade 2.2), and Korea/ES223N/03xPR8 (clade 2.5)]. Although relatively low cross-reactivities (10-40 HI titer) were observed against heterologous H5N8 virus, immunized animals were 100% protected from challenge with the 20 mLD[SUB]50[/SUB] of H5N8 virus, with the exception of mice vaccinated with 3.5μg of Rg Vietnam/1194/04xPR8. Of note, the Rg Korea/ES223N/03xPR8 vaccine provided not only effective protection, but also markedly inhibited viral replication in the lungs and nasal swabs of vaccine recipients within five days of HPAI H5N8 virus challenge. Further, we demonstrated that antibody-dependent cell-mediated cytotoxicity (ADCC) of an antibody-coated target cell by cytotoxic effector cells also plays a role in the heterologous protection of H5N1 vaccines against H5N8 challenge.
Copyright ? 2016 Elsevier Inc. All rights reserved.
[h=4]KEYWORDS:[/h] ADCC; Cross-protection; H5N8; HPAI H5N1; Vaccine
PMID: 27543757 DOI: 10.1016/j.virol.2016.08.010
[PubMed - as supplied by publisher]
[h=1]Cross-protective efficacies of highly-pathogenic avian influenza H5N1 vaccines against a recent H5N8 virus.[/h] Park SJ[SUP]1[/SUP], Si YJ[SUP]1[/SUP], Kim J[SUP]2[/SUP], Song MS[SUP]1[/SUP], Kim SM[SUP]1[/SUP], Kim EH[SUP]1[/SUP], Kwon HI[SUP]1[/SUP], Kim YI[SUP]1[/SUP], Lee OJ[SUP]1[/SUP], Shin OS[SUP]3[/SUP], Kim CJ[SUP]4[/SUP], Shin EC[SUP]2[/SUP], Choi YK[SUP]5[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] To investigate cross-protective vaccine efficacy of highly-pathogenic avian influenza H5N1 viruses against a recent HPAI H5N8 virus, we immunized C57BL/6 mice and ferrets with three alum-adjuvanted inactivated whole H5N1 vaccines developed through reverse-genetics (Rg): [Vietnam/1194/04xPR8 (clade 1), Korea/W149/06xPR8 (clade 2.2), and Korea/ES223N/03xPR8 (clade 2.5)]. Although relatively low cross-reactivities (10-40 HI titer) were observed against heterologous H5N8 virus, immunized animals were 100% protected from challenge with the 20 mLD[SUB]50[/SUB] of H5N8 virus, with the exception of mice vaccinated with 3.5μg of Rg Vietnam/1194/04xPR8. Of note, the Rg Korea/ES223N/03xPR8 vaccine provided not only effective protection, but also markedly inhibited viral replication in the lungs and nasal swabs of vaccine recipients within five days of HPAI H5N8 virus challenge. Further, we demonstrated that antibody-dependent cell-mediated cytotoxicity (ADCC) of an antibody-coated target cell by cytotoxic effector cells also plays a role in the heterologous protection of H5N1 vaccines against H5N8 challenge.
Copyright ? 2016 Elsevier Inc. All rights reserved.
[h=4]KEYWORDS:[/h] ADCC; Cross-protection; H5N8; HPAI H5N1; Vaccine
PMID: 27543757 DOI: 10.1016/j.virol.2016.08.010
[PubMed - as supplied by publisher]